ViiV Healthcare Says Phase III Data From VIKING-3 Dolutegravir Study Encouraging

Published: Nov 14, 2012

ViiV Healthcare, a developer of HIV therapies run by GlaxoSmithKline PLC (GSK.LN)and Pfizer (PFE), Tuesday said it is encouraged by encouraged by the results from the VIKING-3 Phase III study evaluating the investigational integrase inhibitor dolutegravir in HIV-1 infected adults with multiple class antiretroviral resistance. MAIN FACTS: -Will get more data phase III in treatment-experienced patients in the coming months -In the study, mean HIV RNA levels declined by 1.4 log10 copies/mL after 7 days of dolutegravir 50 milliong twice- daily treatment was added to the current failing regimen; 95% confidence interval for the difference.

Back to news